New Enterprise Associates 14, L.P. Insider Trading $ADAP Adaptimmune Therapeutics PLC
Get free email notifications about insider trading for New Enterprise Associates 14, L.P..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of New Enterprise Associates 14, L.P.. New Enterprise Associates 14, L.P. is 10% Owner in MULESOFT, INC ($MULE) and 10% Owner in Tracon Pharmaceuticals, Inc. ($TCON) and 10% Owner in APPIAN CORP ($APPN) and 10% Owner in Mersana Therapeutics, Inc. ($MRSN) and 10% Owner in Mirna Therapeutics, Inc. ($MIRN) and 10% Owner in Cerecor Inc. ($CERC) and 10% Owner in Galera Therapeutics, Inc. ($GRTX) and 10% Owner in Loxo Oncology, Inc. ($LOXO) and 10% Owner in Casper Sleep Inc. ($CSPR) and 10% Owner in Adaptimmune Therapeutics PLC ($ADAP) and 10% Owner in IMARA Inc. ($IMRA) and 10% Owner in Oyster Point Pharma, Inc. ($OYST) and 10% Owner in Surface Oncology, Inc. ($SURF).
New Enterprise Associates 14, L.P. in Adaptimmune Therapeutics PLC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of New Enterprise Associates 14, L.P.: 10% Owner
Holdings: 82,978,668 shares
Current Value: $375,893,366
Latest Transaction: Sep 10 2018
$ADAP Market Capitalization: $321.36M
$ADAP Previous Close: $4.53
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of New Enterprise Associates 14, L.P. in Adaptimmune Therapeutics PLC
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ADAP, APPN, CSPR, CERC, GRTX, IMRA, LOXO, MRSN, MULE, OYST, SURF, SYBX, TCON
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 10 2018 | ADAP | Adaptimmune Therap ... | New Enterprise Associates 14, ... | 10% Owner | Buy | P | 1.67 | 3,000,000 | 5,000,100 | 82,978,668 | 80 M to 83 M (+3.75 %) |
| Mar 28 2018 | ADAP | Adaptimmune Therap ... | New Enterprise Associates 14, ... | 10% Owner | Buy | P | 1.92 | 6,000,000 | 11,500,200 | 79,978,672 | 74 M to 80 M (+8.11 %) |
| Mar 28 2018 | ADAP | Adaptimmune Therap ... | New Enterprise Associates 14, ... | 10% Owner | Buy | P | 1.90 | 571,164 | 1,087,553 | 73,978,672 | 73.4 M to 74 M (+0.78 %) |
| Mar 23 2018 | ADAP | Adaptimmune Therap ... | New Enterprise Associates 14, ... | 10% Owner | Buy | P | 1.95 | 294,090 | 572,358 | 73,407,508 | 73.1 M to 73.4 M (+0.40 %) |
| Mar 23 2018 | ADAP | Adaptimmune Therap ... | New Enterprise Associates 14, ... | 10% Owner | Buy | P | 1.90 | 869,574 | 1,655,669 | 73,113,418 | 72.2 M to 73.1 M (+1.20 %) |
| Mar 23 2018 | ADAP | Adaptimmune Therap ... | New Enterprise Associates 14, ... | 10% Owner | Buy | P | 1.81 | 104,844 | 189,820 | 72,243,844 | 72.1 M to 72.2 M (+0.15 %) |
| Mar 28 2017 | ADAP | Adaptimmune Therap ... | New Enterprise Associates 14, ... | 10% Owner | Buy | P | 0.70 | 12,870,000 | 9,009,000 | 72,139,000 | 59.3 M to 72.1 M (+21.71 %) |
Page: 1